Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Filings indexed 679 across all filing types
Latest filing 2025-12-04 Director's Dealing
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-12-04 English
Regulatory Filings 2025
Regulatory Filings
2025-12-01 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-10 English
8-K
Regulatory Filings
2025-11-10 English
8-K
Regulatory Filings
2025-10-09 English
FORM 4
Director's Dealing
2025-09-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.